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ThepurposeofthisstudywastodeterminewhetherAVE7688adrugthatinhibitsbothangiotensinconvertingenzymeandneutral
endopeptidase activity protects vascular and nerve functions in an animal model of metabolic syndrome. Obese Zucker rats at 20
weeks of age were treated for 12 weeks with AVE7688. Vasodilation in epineurial arterioles was measured by videomicroscopy and
nerve conduction velocity was measured following electrical stimulation. Treatment with AVE7688 improved vascular relaxation
in response to acetylcholine and motor and sensory nerve conduction velocity. In obese Zucker rats superoxide levels and
nitrotyrosine staining were elevated in the aorta and treatment corrected both conditions. Obese Zucker rats were hypoalgesic
in response to a thermal stimulus and demonstrated signs of impaired tactile response and both conditions were signiﬁcantly
improved with treatment. Even though obese Zucker rats are normoglycemic vascular and neural dysfunctions develop with age
and can be improved by treatment with AVE7688.
Copyright © 2009 Eric P. Davidson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Patients with impaired glucose tolerance, a feature of meta-
bolic syndrome, have been described by some investigators
as developing peripheral neuropathy with microvascular dis-
ease [1–4]. Also, patients with type 2 diabetes and metabolic
syndrome have a higher incidence of diabetic neuropathy
than diabetic patients without metabolic syndrome [4–7].
However, other investigators state that it is unclear whether
impaired glucose tolerance is associated with diabetic sen-
sorimotor polyneuropathy or chronic idiopathic axonal
polyneuropathy and that some of the disparities may be due
to diﬀerences in patient selection, assessment of glycemic
exposure, and diabetic complications [8]. Nonetheless, there
is a need for further study to determine whether patients
with metabolic syndrome may be at increased risk for
microvascular disease and peripheral neuropathy.
Previously, we demonstrated that obese Zucker rats,
a model for metabolic syndrome, develop microvascular
and neural deﬁcits independently of hyperglycemia [9].
In obese Zucker rats, impaired relaxation in response to
acetylcholine in epineurial arterioles and slowing of motor
nerve conduction velocity were observed after 16–20 and 32
weeks of age, respectively, demonstrating that microvascular
impairment preceded neural dysfunction. In the present
study we sought to determine whether treatment of obese
Zucker rats with AVE7688, a vasopeptidase inhibitor, for
12 weeks beginning at 20 weeks of age could improve
microvascular dysfunction and prevent the slowing of
nerve conduction velocity. Vasopeptidase inhibitors are a
new class of drug that simultaneously inhibits neutral
endopeptidase and angiotensin converting enzyme (ACE)
activity[10].Recentstudieshaveshownincreasedexpression
of angiotensin II-forming enzymes in adipose tissue, and
increased activity of the renin-angiotensin system has been
implicated in the development of insulin resistance and type
2 diabetes [11]. Neutral endopeptidase is found in many
tissues including vascular tissue and its activity is increased
by fatty acids and glucose in human microvascular cells
[12–16]. Neutral endopeptidase degrades many vasoactive2 Experimental Diabetes Research
peptides including natriuretic peptides, adrenomedullin,
bradykinin, and calcitonin gene-related peptide [17, 18].
Therefore, inhibition of ACE and neutral endopeptidase
activity would be expected to improve vascular function.
In this regard, vascular conductance in the femoral artery
of streptozotocin-induced diabetic rats to bradykinin was
improved by a vasopeptidase inhibitor and we have shown
that vasodilation by epineurial arterioles to acetylcholine
and nerve function are improved in streptozotocin-induced
diabetic rats and Zucker diabetic fatty rats (ZDF) treated
with AVE7688 [19–21]. Vasopeptidase inhibitors have also
been shown to be neuroprotective and prevent nephropathy
in ZDF rats and decrease matrix metalloproteinases, AGE
accumulation/formation in type 2 diabetes and improve
woundhealing[22–28].Therefore,thereisgreatpotentialfor
treatment of vascular and neural dysfunctions with vasopep-
tidase inhibitors; however, no information is available about
theeﬀectoftheseinhibitorsinananimalmodelwithfeatures
of metabolic syndrome.
2.MaterialsandMethods
Unless stated otherwise all chemicals used in these studies
were obtained from Sigma Chemical Co. (St. Louis, MO).
2.1. Animals. Male Zucker rats, obese and lean, were
obtained at 6 weeks of age from Charles River Laboratories,
Wilmington, MA. The lean animals were not genotyped and
could have been either +/+ or +/− for the leptin receptor
deletion. The animals were housed in a certiﬁed animal care
facilityandfood(HarlanTeklad,no.7001,Madison,WI)and
water were provided ad libitum. All institutional and NIH
guidelines for use of animals were followed.
A t2 0w e e k so fa g et h eo b e s eZ u c k e rr a t sw e r ed i v i d e d
into two groups. One group was fed the standard chow
diet. The second group was fed the standard chow diet
containing 500mg/kg AVE7688. Based on the amount of
chow consumed the rats received approximately 30mg/kg
rat/day of AVE7688. The supplemented diet was prepared by
thoroughly mixing the AVE7688 into the meal form of the
diet for 1 hour. Afterwards, the diet was pelleted and dried
i nav a c u u mo v e ns e ta t4 0 ◦C overnight. The control diet was
also prepared from meal. The treatment period lasted for 12
weeks.
2.2. Thermal Nociceptive and Tactile Response Threshold. The
day before the terminal studies, tactile response threshold
was measured with von Frey ﬁlaments using the modiﬁed
up-down method [29–31]. Six hours later thermal noci-
ceptive response in the hindpaw was measured using the
Hargreaves method with instrumentation provided by IITC
Life Science; Woodland Hills, CA (model 390G). These tests
were performed when possible in a blind manner with
the operator not knowing whether the obese Zucker rat
was in the treatment or nontreated group. For the tactile
response threshold measurement the rat was placed on a
wire mesh grid and allowed to acclimate for 15 minutes.
Afterwards, a von Frey ﬁlament was applied to the left
hindpaw. Continuous pressure with the ﬁlament was applied
for 5 seconds. If the animal lifted its paw, a positive response,
then the next ﬁlament with less force was applied to the
paw. If the animal did not respond, a negative response,
then the next ﬁlament with increasing force was used. This
process was continued until four measurements following
the initial positive response were recorded. The results were
quantiﬁed according to Chaplan et al. [29]. For the thermal
nociceptive response measurement the rat was placed in the
observation chamber on top of the thermal testing apparatus
and allowed to acclimate to the warmed glass surface (30◦C)
and surroundings for a period of 15 minutes. The mobile
heat source was maneuvered so that it was under the heal
of the hindpaw and then activated, a process that activates
a timer and locally warms the glass surface, when the rat
withdrew its paw, the timer, and the heat source was turned
oﬀ [32]. Following an initial recording, which was discarded,
four measurements were made for each hindpaw, with a rest
period of 5 minutes between each set of measurements. The
mean of the measurements, reported in seconds, were used
as a measure of the thermal nociceptive response.
On the day of the terminal experiments, rats were
anesthetized with Nembutal i.p. (50mg/kg, i.p., Abbott
Laboratories, North Chicago, IL) and nonfasting blood
glucose levels were determined with the use of glucose
oxidase reagent strips (Lifescan Inc., Milpitas, CA). Serum
samples were collected for determination of insulin levels
using a Luminex 100 system. The insulin analyte kit
was purchased from Upstate, Charlottesville, VA. Levels
of serum-free fatty acid, triglyceride, free cholesterol, and
ACE activity were determined using commercial kits from
Roche Diagnostics, Mannheim, Germany; Sigma Chemical
Co., St. Louis, MO; Bio Vision, Mountain View, CA; and
ALPCO, diagnostics, Salem, NH; respectively. In all analyses
the manufactures instructions were followed. Afterwards,
motor and sensory nerve conduction velocity was deter-
mined and tissue containing the epineurial arterioles was
collected.
2.3. Motor and Sensory Nerve Conduction Velocity. Motor
nerve conduction velocity (MNCV) was determined as
previously described using a noninvasive procedure in the
sciatic-posterior tibial conducting system [33–36]. Sensory
nerve conduction velocity (SNCV) was determined using the
digitalnervetothesecondtoeasdescribedbyObrosovaet al.
[37]. The MNCV and SNCV were reported in meters per
second.
2.4. Vascular Reactivity. Videomicroscopy was used to inves-
tigate in vitro vasodilatory responsiveness of arterioles
vascularizing the region of the sciatic nerve as previously
described [33–36]. The average lumen diameter of the
epineurial arterioles used in these studies was about 100μm.
Based on size and function these vessels can be considered
to be microvessels. Cumulative concentration-response rela-
tionships were evaluated for acetylcholine (10
−8–10
−4 M)
using vessels from each group of rats. At the end of each
dose response determination a maximal dose of sodium
nitroprusside (10
−4 M) was added. Afterwards, papaverine
(10
−5 M) was added to determine maximal vasodilation.Experimental Diabetes Research 3
2.5. Detection of Superoxide and Peroxynitrite. Using the
aorta superoxide levels were measured by lucigenin-
enhanced chemiluminescence as described previously [38].
Relative light units (RLU) were measured using a luminome-
ter. Background activity was determined and subtracted and
RLU was normalized to surface area.
One mechanism by which acetylcholine can mediate
vascular relaxation in arterioles that provide circulation to
the sciatic nerve is through the production of nitric oxide
[39]. The chemistry of nitric oxide is complex, and several
biochemicalpathwaysotherthannitricoxideproductioncan
inﬂuence nitric oxide bioactivity. For example, superoxide
anion can interact with nitric oxide to form peroxynitrite
[40]. This reaction reduces the eﬃcacy of nitric oxide to
act as a signal transduction agent. Peroxynitrite is a highly
reactive intermediate known to nitrate protein tyrosine
residues and cause cellular oxidative damage [40, 41]. To
determine whether formation of superoxide by the aorta
promotes the formation of peroxynitrite we measured 3-
nitrotyrosine (3-nitrotyrosine is a stable biomarker of tissue
peroxynitrite formation) in vessel sections from 32-week old
lean and obese Zucker rats treated with or without AVE7688.
Brieﬂy, frozen tissue segments of aorta were cut into 10 μm
sections and then incubated in phosphate buﬀered saline
solution containing 1% Triton X-100 and 0.1% bovine
serum albumin for 30 minutes at room temperature. After-
wards, the samples were incubated overnight at 4◦C in this
buﬀer solution containing mouse antinitrotyrosine antibody
(Upstate, Lake Placid, NY). After washing, the sections were
incubated for 2 hours with Alexa Fluor 555 goat antimouse
IgG (Molecular Probes, Eugene, OR). Sections were then
rinsed and mounted with VectorShield. The labeled vessels
derived from these studies were visualized with an Olympus
IX71 inverted research microscope interfaced with a PC
containing SimplePCI imaging software. Pixel intensity for
nitrotyrosine immunostaining was determined for each
vessel segment and averaged for each condition.
2.6. Data Analysis. The results are presented as mean
±SE. Comparisons between the groups for body weight,
blood glucose, MNCV, SNCV, thermal nociception, tactile
allodynia, serum TBARS, serum free fatty acid, triglyceride,
cholesterol and insulin levels, serum ACE activity, aorta
superoxide and nitrotyrosine levels were conducted using
a one-way ANOVA and Newman-Keuls test for multiple
comparisons and Bonferroni-Dunn test (Prism software;
GraphPad, San Diego, CA). Concentration response curves
for acetylcholine- and CGRP-induced relaxation were com-
paredusingatwo-wayrepeatedmeasuresanalysisofvariance
with autoregressive covariance structure using a proc mixed
program of SAS [33–36]. Whenever signiﬁcant interactions
were noted speciﬁc treatment-dose-eﬀects were analyzed
using a Bonferroni-Dunn test. A P value of less 0.05 was
considered signiﬁcant.
3. Results
Data in Table 1 demonstrate that lean and obese Zucker rats
weighed about the same at 6 weeks of age. However, by 32
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Figure 1: Determination of the eﬀect of treatment of obese Zucker
rats with AVE7688 for 12 weeks at 20 weeks of age on motor
and sensory nerve conduction velocity. Data are presented as
the mean±SEM in meters/second. The number of experimental
determinations is presented in parenthesis. ∗P<. 05, compared
to lean rats, +P<. 05 compared to untreated obese Zucker rats.
weeks of age obese Zucker rats weighed signiﬁcantly more
then the lean control rats and treatment with AVE7688 did
notinﬂuenceweightgaininobeseZuckerrats.Bloodglucose
levels were not signiﬁcantly diﬀerent between lean rats and
treated or untreated obese Zucker rats. Insulin levels were
signiﬁcantly increased in obese Zucker rats compared to lean
rats. Furthermore, treating obese Zucker rats with AVE7688
increased insulin levels. Free cholesterol levels tended to
be higher in both untreated and treated obese Zucker rats
but compared to the lean controls this diﬀerence did not
reachstatisticalsigniﬁcance.Serumtriglycerideandfreefatty
acid levels were signiﬁcantly increased in obese Zucker rats
compared to lean rats and lowered with treatment of obese
Zucker rats with AVE7688. Serum ACE activity was also
signiﬁcantly increased in obese Zucker rats and lowered with
treatment of AVE7688.
Data in Figure 1 demonstrate that in obese Zucker rats
at 32 weeks of age motor and sensory nerve conduction
velocity was signiﬁcantly decreased compared to lean control
rats. Treating obese Zucker rats for 12 weeks with AVE7688
prevented the slowing of nerve conduction velocity.
Data in Table 1 demonstrate that after 32 weeks of age
obese Zucker rats develop thermal hypoalgesia and have an
impaired tactile response threshold. Treating obese Zucker
rats with AVE7688 signiﬁcantly improved the impairment in
pain perception.
Data in Figure 2 demonstrate that acetylcholine-
mediated vascular relaxation is decreased in epineurial
arterioles of the sciatic nerve from obese Zucker rats at
32 weeks of age compared to lean rats. Relaxation to
maximal dosage of sodium nitroprusside (10
−4 M) was also
signiﬁcantly decreased in obese Zucker rats compared to
lean control rats (89.6 ± 4.4% and 58.8 ± 6.7%, resp.).
Treating obese Zucker rats at 20 weeks of age with AVE7688
for 12 weeks signiﬁcantly reduced the extent of vascular
impairment.4 Experimental Diabetes Research
Table 1: Eﬀect of obesity and treatment with AVE7688 on body weight, blood glucose, serum insulin, cholesterol, triglycerides, free fatty
acids, and ACE activity, and thermal nociception and tactile allodynia.
Determination Lean (17) Obese (9) Obese + AVE7688 (14)
Start weight (g) 190 ± 4 216 ± 7 216 ± 7
End weight (g) 522 ± 9 785 ± 33∗ 842 ± 21∗
Blood glucose (mg/dL) 84 ± 59 6 ± 9 116 ± 15
Insulin (ng/mL) 7.7 ± 2.51 6 .7 ± 1.5∗ 71.6 ± 19.3∗+
Cholesterol (mg/mL) 6.0 ± 0.61 8 .0 ± 3.5∗ 15.9 ± 4.0
Triglycerides (mg/dL) 2.53 ± 0.40 13.60 ± 2.14∗ 8.21 ± 1.68∗
Free fatty acids (mmol/L) 0.13 ± 0.04 0.63 ± 0.23∗ 0.22 ± 0.03
ACE activity (U/l) 37.5 ± 3.4 211.2 ± 26.4∗ 38.0 ± 5.7+
Thermal nociception (sec) 12.8 ± 0.42 0 .3 ± 0.8∗ 15.4 ± 0.9+
Tactile 50% response threshold (g) 9.8 ± 1.21 6 .6 ± 1.6∗ 10.1 ± 1.3+
Data are presented as the mean±SEM. ∗P<. 05 compared to lean, +P<. 05 compared to obese. Parentheses indicate the number of experimental animals.
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Figure 2: Determination of the eﬀect of treatment of obese Zucker
rats with AVE7688 for 12 weeks at 20 weeks of age on acetylcholine-
mediated vascular relaxation of epineurial arterioles of the sciatic
nerve. Pressurized arterioles (40mm Hg) were constricted with
U46619 (30–50%) and incremental doses of acetylcholine were
added to the bathing solution while recording steady state vessel
diameter. Data are presented as the mean of % relaxation±SEM.
The number of experimental determinations is presented in
parenthesis. ∗P<. 05, compared to lean rats, +P<. 05 compared
to untreated obese Zucker rats.
In order to obtain information on the oxidative stress
status of the vasculature of untreated and treated obese
Zucker rats we performed analysis of superoxide levels
and nitrotyrosine staining of the aorta. The data obtained
with the aorta does not necessarily reﬂect the oxidative
stress conditions of epineurial arterioles but does serve as a
marker of oxidative stress in vascular tissue and the eﬀect
of treatment. Data in Figure 3 demonstrate that superoxide
levels and nitrotyrosine staining are increased in aortas of
obese Zucker rats compared to lean rats at 32 weeks of
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Figure 3: Determination of aorta superoxide and nitrotyrosine in
epineurial arterioles of the sciatic nerve from lean and obese Zucker
rats treated with AVE7688. Presented are representative ﬂuorescent
photomicrographs of confocal microscopic sections of aorta for
nitrotyrosinestaining.Lucigenin-basedassaywasusedtodetermine
superoxide levels in the aorta. The graphed data are presented as
arbitrary light units with the value for lean rats assigned as 1. ∗P<
.05 compared to untreated obese Zucker rats. These values were
obtained from 2 diﬀerent rats and 5 vessel segments were analyzed
for each individual rat.
age. Treating obese Zucker rats with AVE7688 signiﬁcantly
reduced the level of superoxide and nitrotyrosine staining in
the aorta.Experimental Diabetes Research 5
4. Discussion
We previously reported that obese Zucker rats develop vas-
cular and neural impairment independent of hyperglycemia
[9]. Furthermore, we demonstrated that impairment in
vascular relaxation to acetylcholine in epineurial arterioles
of the sciatic nerve preceded the slowing of nerve con-
duction velocity [9]. We have made similar observations
in streptozotocin-induced diabetic rats and ZDF rats [35,
42, 43]. In these diabetic rat models vascular and neural
dysfunctions appeared earlier than in Zucker rats, which
we attribute to the inﬂuence of hyperglycemia. However,
the observation that vascular and neural dysfunctions can
occur in the absence of hyperglycemia is important and
could have implications in patient care if these results
are translatable to humans. In this regard, it has been
shown that small ﬁber neuropathy exists in patients with
metabolic syndrome and may be an early marker of sensory
neuropathy [44]. The neuropathy associated with impaired
glucose tolerance is milder than the neuropathy associated
with diabetes but has been syndromically linked to the
typical painful polyneuropathy seen in diabetic patients
[45, 46].
Based on our previous results the obese Zucker rat is
an appropriate animal model to study development and
progression of neuropathy independent of hyperglycemia
[9]. The current study demonstrate that the sensory neu-
ropathy that occurs is characterized by a slowing of sensory
nerveconductionvelocity,thermalhypoalgesiaandimpaired
tactile response when obese Zucker rats are 32 weeks of
age. It is unknown whether obese Zucker rats at an earlier
age experience thermal hyperalgesia as been shown in early
stages of diabetic neuropathy in streptozotocin treated rats
[31, 47]. Furthermore, it is unknown whether obese Zucker
rats at later stages experience a loss in intraepidermal
nerve ﬁber density, which may explain the decrease in pain
perception in the hindpaw. The answer to these questions
will require further study.
Given that obesity and prediabetes within the population
is reaching epidemic levels there is a need to identify
eﬀective therapies for complications that occur with these
conditions. Vasopeptidase inhibitors are a new class of
drug that inhibits both angiotensin converting enzyme and
neutral endopeptidase. Thus, these drugs have the potential
to enhance vasodilation properties of peptides that are
degraded by neutral endopeptidase such as the natriuretic
peptides, bradykinin, calcitonin gene related peptide and
adrenomedullin as well as inhibit the production of the
vasoconstrictor angiotensin II [10, 18]. In several hyperten-
sion prone rat models vasopeptidase inhibitors have been
shown to reduce hypertension and cardiac hypertrophy [17,
18, 48, 49]. In ZDF rats, a model for type 2 diabetes,
and spontaneously hypertensive rats (SHR) vasopeptidase
inhibitor treatment prevented nephropathy [22, 23, 50]. Our
previous studies demonstrated that treating streptozotocin-
induced diabetic rats and ZDF rats with AVE7688 improved
vasodilationofepineurialarteriolesofthesciaticnerve,nerve
conduction velocity and blood ﬂow in the sciatic nerve
[20, 21].
InthecurrentstudyweexaminedtheeﬃcacyofAVE7688
on vascular and neural dysfunctions in obese Zucker rats.
Treatment was started at 20 weeks of age and studies
performed when the rats were 32 weeks of age. At 20 weeks
of age vascular relaxation to acetylcholine by epineurial
arterioles is impaired but motor nerve conduction velocity
is normal [9]. By 32 weeks of age both vascular and neural
functions were impaired [9]. Treating obese Zucker rats with
AVE7688 improved both vascular and neural dysfunctions
and responsiveness to a painful stimulus.
The improvement in vascular function may be due to
several mechanisms. First, there is an increase in superox-
ide and nitrotyrosine staining in vascular tissue of obese
Zucker rats [9]. This could lead to quenching of nitric
oxide one of two mechanisms responsible for acetylcholine-
mediated vascular relaxation in epineurial arterioles [39].
Treating obese Zucker rats with AVE7688-reduced markers
of oxidative stress in vascular tissue. Second, we previously
demonstrated that acetylcholine induced vascular relaxation
in epineurial arterioles is also mediated by the formation
of endothelium-derived hyperpolarizing factor (EDHF) and
that C-type natriuretic peptide (CNP) meets several of the
criteria of EDHF in these vessels [19, 38, 50]. We have
shown that epineurial arterioles express CNP and that CNP-
induced vasodilation of epineurial arterioles is decreased by
diabetes [20]. Treating diabetic rats with AVE7688 protected
acetylcholine- and CNP-mediated vasodilation of epineurial
arterioles [20]. Thus, protection of CNP from degradation
could also contribute to improved acetylcholine-mediated
vascularrelaxationinepineurialarteriolesfromobeseZucker
rats. However, it should be noted that the impairment
of vascular relaxation to acetylcholine was not completely
prevented by treating obese Zucker rats with AVE7688. This
contrastswithourstudiesinstreptozotocin-induceddiabetic
rats and ZDF rats [20, 21]. In those studies treatment
with AVE7688 completely restored acetylcholine-mediated
vascular relaxation. This could be due to other factors such
as hyperlipidemia contributing to vascular impairment in
obese Zucker rats. In a previous study we found that treating
obese Zucker rats with Enalapril or Rosuvastatin improved
acetylcholine-mediated vascular relaxation in epineurial
arterioles to a similar extent as AVE7688. In that study
as well as in this study treatment was not able to fully
correct the hyperlipidemia [51]. A more aggressive therapy
aimed at lowering lipids in combination with AVE7688
may be necessary to completely restore vascular function in
epineurial arterioles.
It has been demonstrated that treating obese Zucker rats
with mixanpril, a vasopeptidase inhibitor, improves insulin
sensitivity in obese Zucker rats [52, 53]. In our studies
treating obese Zucker rats with AVE7688 increased serum
insulinlevelsat32weeksofage.Previously,wedemonstrated
that serum insulin levels peak at about 16 weeks of age
and then gradually decline to levels observed in lean rats at
about 40 weeks of age [9]. Treating obese Zucker rats with
AVE7688 maintained serum insulin at levels comparable to
those observed in a younger animal. Insulin resistance is
an important risk factor for endothelial dysfunction [54]. It
has been shown that improving insulin sensitivity improves6 Experimental Diabetes Research
vascular resistance in obese Zucker rats [55]. Insulin has
also been shown to be a vasodilator in many vessel beds
and causes vascular relaxation in epineurial arterioles of the
sciatic nerve (unpublished results). Therefore,the increase in
insulin levels could have contributed to the overall improved
vascular function seen in obese Zucker rats treated with
AVE7688 and this could improve blood ﬂow to peripheral
nerves and thereby nerve function.
Motor and sensory nerve conduction velocity as well
as behavioral responsiveness to a painful stimulus was
signiﬁcantly improved by treatment of obese Zucker rats
with AVE7688. This was similar to the eﬀect of AVE7688
treatment of streptozotocin-induced diabetic rats and ZDF
ratsandEnalapriltreatmentofobeseZuckerrats[20,21,51].
Comparing the overall eﬃcacy of Enalapril and AVE7688
treatment of obese Zucker rats we ﬁnd not much of a
diﬀerence [51] .B o t hd r u g sa p p e a rt ob ee ﬀective to the
same extent in improving vascular and nerve dysfunctions
inthisanimalmodel.WepreviouslyconcludedthatAVE7688
treatmentofdiabeticratswasmoreeﬃcaciousthenEnalapril
[56]. The reason for this diﬀerence is unknown but may
be due to the greater role hyperlipidemia may have on
complications in the obese Zucker rat.
It is intriguing to speculate on the mechanism respon-
sible for thermal hypoalgesia in 32-week-old obese Zucker
rats. This is the ﬁrst report of impaired pain perception
in obese Zucker rats. As stated above, we do not know
at this time whether intraepidermal nerve ﬁber density is
decreased at this age in obese Zucker rats. However, it
has been reported that in skin biopsies from patients with
metabolic sydrome there is a decrease in mean dendrite
length [44]. In streptozotocin-, cisplatin-, and paclitaxel-
induced neuropathy slowing in sensory nerve conduction
velocity correlated with intraepidermal nerve ﬁber density
quantiﬁcation [57]. Thus, a decrease in intraepidermal
nerve ﬁber density in older obese Zucker rats would not
be surprising and could explain the decrease in pain
perception in these rats. Our ﬁnding that obese Zucker
rats are less sensitive to a mechanical stimulus diﬀers
from previous studies in streptozotocin-diabetic rat models
where tactile allodynia is a common ﬁnding [31, 32, 47].
The reason for this diﬀerence between these models is
unknown and requires conﬁrmation. However, such a ﬁnd-
ing could have important implications in patient care and
management.
5. Conclusions
The important ﬁndings from this study was that 12 weeks
of treatment of obese Zucker rats, an animal model
of metabolic syndrome, with AVE7688, a vasopeptidase
inhibitor that simultaneously inhibits angiotensin convert-
ing enzyme and neutral endopeptidase activity, improves
microvascular and nerve functions as well as impaired pain
perception in animals 32 weeks of age. This new class of drug
that has been previously shown to improve cardiovascular
and renal dysfunctions may be an eﬀective approach for
the treatment of a number of complications associated with
metabolic syndrome and diabetes.
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